New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
06:00 EDTCLVSClovis announces first patient enrolled in TIGER2 study
Clovis Oncology announced that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is the Company’s novel, oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M.
News For CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CLVS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use